



DRUG QUANTITY MANAGEMENT POLICY – PER RX

- POLICY:** Oncology (Oral – Bruton's Tyrosine Kinase Inhibitor) – Calquence DQM Policy – Per Rx
- Calquence® (acalabrutinib capsules [discontinued] and tablets – AstraZeneca)

REVIEW DATE: 07/02/2025

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Calquence, a Bruton's tyrosine kinase (BTK) inhibitor, is indicated in adults for the following uses:^{1,2}

- **Chronic lymphocytic leukemia (CLL)** or **small lymphocytic leukemia (SLL)**.
- **Mantle cell lymphoma**, previously untreated, in combination with bendamustine and rituximab in patients who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
- **Mantle cell lymphoma (MCL)**, in patients who have received at least one prior therapy.

Dosing

Monotherapy

The recommended dose of Calquence for treatment of MCL, CLL, or SLL, is 100 mg orally every 12 hours until disease progression or unacceptable toxicity.^{Error! Reference source not found.}

Combination with Obinutuzumab

For the treatment of CLL or SLL in previously untreated patients, the recommended dose of Calquence is 100 mg orally every 12 hours until disease progression or unacceptable toxicity.¹ Each treatment cycle is 28 days. Calquence should be started at Cycle 1 and obinutuzumab at Cycle 2, for a total of 6 cycles.

Combination with Bendamustine and Rituximab

For the treatment of MCL in previously untreated patients, the recommended dose of Calquence is 100 mg orally every 12 hours until disease progression or unacceptable toxicity.¹ Each treatment cycle is 28 days. Calquence, bendamustine, and rituximab should be started at Cycle 1 for a total of 6.

The dose may need to be reduced or withheld due to adverse events, hematological toxicities or drug interactions with cytochrome P450 (CYP)3A inhibitors.¹ CYP3A inducers may decrease Calquence plasma concentrations; therefore, a dose of 200 mg every 12 hours is recommended, as tolerated, in patients taking strong CYP3A4 inducers (e.g., apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort).

Availability

Calquence is available in 100 mg capsules (discontinued) and tablets supplied in bottles of 60.¹

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Calquence. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity Per Rx	Home Delivery Maximum Quantity Per Rx
Calquence® (acalabrutinib capsules/tablets)	100 mg capsules (discontinued)	60 capsules	180 capsules
	100 mg tablets	60 tablets	180 tablets

EXCEPTIONS TO THE QUANTITY LIMITS LISTED ABOVE ARE COVERED AS MEDICALLY NECESSARY WHEN THE FOLLOWING CRITERIA ARE MET. ANY OTHER EXCEPTION IS CONSIDERED NOT MEDICALLY NECESSARY.

CRITERIA

1. If the patient is taking a strong cytochrome P450 (CYP)3A inducer, approve 120 capsules or tablets per dispensing at retail and 360 capsules or tablets per dispensing at home delivery.

Note: Examples of CYP3A inducers include, but are not limited to, apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, and St. John's wort.

REFERENCES

1. Calquence® capsules [prescribing information]. Wilmington, DE: AstraZeneca; January 2025.
2. Calquence® tablets [prescribing information]. Wilmington, DE: AstraZeneca; January 2025.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	06/15/2023
Annual Revision	No criteria changes	07/01/2024
Annual Revision	The policy name was changed from "Oncology – Calquence DQM Policy – Per Rx" to "Oncology (Oral – Bruton's Tyrosine Kinase Inhibitor) – Calquence DQM Policy – Per Rx". No criteria changes.	07/02/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.